

## Use of the Glasgow-Blatchford score during the COVID-19 pandemic needs more rigorous research

A very important paper by Young-II Kim et al. [1] was published recently in *Endoscopy*. The authors found that the Glasgow-Blatchford score (GBS) was inferior to the Rockall score in predicting the need for urgent hemostatic intervention for tumor-associated upper gastrointestinal bleeding (UGIB), leading to poor performance (area under the receiver operating characteristic curve [AUROC] 0.56). This study is crucial for patient risk stratification for UGIB during the COVID-19 pandemic, and we would like to draw your attention toward it.

The COVID-19 pandemic has severely affected the practice of gastrointestinal (GI) endoscopy worldwide because upper GI endoscopy has been recognized as an aerosol-generating procedure that increases the risk of COVID-19 infection [2]. Thus, the endoscopic management of patients with UGIB now presents a dilemma. The pre-endoscopy risk scores, such as GBS, are based on pre-pandemic research and have not been validated by large-scale studies during the COVID-19 pandemic. A recent case series [3] has shown that six UGIB patients with COVID and GBS >7 did not require endoscopy and were conservatively managed, which did not accord with the relevant European Society for Gastrointestinal Endoscopy (ESGE) guideline [4]. The latter recommends only that patients with a GBS score of 0–1 do not require endoscopy. Thus, the performance of the GBS has seemed to be especially limited during the COVID-19 pandemic [3]. According to Laursen et al. [5], the low-risk threshold for defining UGIB patients who do not require inpatient endoscopy and hospitalization could be increased to GBS <3.

In conclusion, the COVID-19 pandemic remains a worldwide challenge, and its impact on GI endoscopy and UGIB detection could be increasingly significant. Raising the GBS threshold or developing a new and accurate risk score before endoscopy in UGIB patients will be critical in the prevention of a UGIB health-care crisis. We hope a more rigorous study will be conducted in the near future.

### Competing interests

The authors declare no conflicts of interest.

### The authors

**Zhihui Duan, Shengyun Zhou, Zongxian Niu**  
Department of Endoscopy, Xingtai People's Hospital, Xingtai 054000, Hebei Province, China

### Corresponding author

**Zhihui Duan, MM**  
Department of Endoscopy, Xingtai People's Hospital, No.16 Hongxing Street, Xingtai 054000, Hebei Province, China  
15131988129@163.com

### References

- [1] Kim YI, Choi IJ, Lee JY et al. Comparison of the performance of risk scoring systems for tumor bleeding in patients with inoperable gastric cancer. *Endoscopy* 2020; 52: 359–367
- [2] Gralnek IM, Hassan C, Beilenhoff U et al. ESGE and ESGENA Position Statement on gastrointestinal endoscopy and the COVID-19 pandemic. *Endoscopy* 2020; 52: 483–490
- [3] Cavaliere K, Levine C, Wander P et al. Management of upper GI bleeding in patients with COVID-19 pneumonia. *Gastrointest Endosc* 2020; 92: 454–455
- [4] Gralnek IM, Dumonceau JM, Kuipers EJ et al. Diagnosis and management of nonvariceal upper gastrointestinal hemorrhage: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. *Endoscopy* 2015; 47: a1–a46
- [5] Laursen SB, Gralnek IM, Stanley AJ. Raising the threshold for hospital admission and endoscopy in upper gastrointestinal bleeding during the COVID-19 pandemic. *Endoscopy* 2020; 52: 930–931

### Bibliography

*Endoscopy* 2021; 53: 209  
DOI 10.1055/a-1300-2132  
ISSN 0013-726X  
published online 19.11.2020  
© 2020. Thieme. All rights reserved.  
Georg Thieme Verlag KG Rüdigerstraße 14,  
70469 Stuttgart, Germany